DXCM - DexCom Inc

DXCM - DexCom Inc

https://www.dexcom.com/global

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm - DexCom ( NASDAQ:DXCM )

Benzinga • 1 hour, 39 minutes ago • score: -0.20

NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. DXCM breached their fiduciary duties to shareholders.

Why Is DexCom ( DXCM ) Down 7% Since Last Earnings Report?

Zacks Commentary • 2 weeks, 3 days ago • score: 0.21

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

P/E Ratio Insights for DexCom - DexCom ( NASDAQ:DXCM )

Benzinga • 2 weeks, 3 days ago • score: 0.35

Looking into the current session, DexCom Inc. DXCM shares are trading at $75.05, after a 0.04% decrease. Over the past month, the stock fell by 5.65%, but over the past year, it actually spiked by 3.37%.

If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today

Motley Fool • 2 weeks, 3 days ago • score: 0.37

The company's innovative devices have helped it generate decent performances.

DexCom Expands Access and Innovation While Balancing Headwinds

Zacks Commentary • 3 weeks, 5 days ago • score: 0.47

DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.

2 Stocks to Buy on the Dip and Hold for 10 Years

Motley Fool • 4 weeks, 2 days ago • score: 0.29

There should be plenty of long-term upside for these stocks for investors willing to ride out the storm.

Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data

Zacks Commentary • 1 month ago • score: 0.29

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

52W High

$93.25

52W Low

$57.52

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.49

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

56.70

Forward P/E (<15 better)

30.86

EV/EBITDA (<8 favorable)

30.04

EV/Revenue (<3 favorable)

7.26

P/S (TTM) (<3 favorable)

7.34

P/B (<3 favorable)

12.27

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.42%

Institutions (25–75% balanced)

97.52%

Shares Outstanding

392,155,000

Float

389,508,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

4,300,800,000

Gross Profit (TTM)

2,527,400,000

EPS (TTM)

1.42

Profit Margin (>10% good)

0.13%

Operating Margin (TTM) (higher better)

0.18%

ROE (TTM) (>15% strong)

0.23%

EPS YoY (Quarterly) (>10% good)

0.27

Revenue YoY (Quarterly) (>8% good)

0.15

Momentum

Bearish momentum

Value

-1.2587

Previous

-1.2016

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025